CYCLOSPORIN A IN RHEUMATOID ARTHRITIS

环孢菌素A（CSA）每日口服的疗效和毒性 活动性类风湿性关节炎患者将在6个月内接受评估， 低剂量（1 mg/kg/天）与高剂量（10 mg/kg/天）的双盲研究 CSA。 前2个月每周监测一次毒性，然后每2个月监测一次毒性。 几周到6个月。 每两个月评估一次疾病活动。 疾病活动性未改善至少40%的患者 在6个月时从研究中删除，而那些具有40%或更大的 反应持续另外6个月的药物治疗。 的影响 CSA对外周血中T淋巴细胞功能的各种指标的影响， 在所有患者中研究滑膜内。

The efficacy and toxicity of daily, oral cyclosporin A (CSA) in patients with active rheumatoid arthritis is being evaluated in a 6 month double-blind study of low dose (1mg/kg/day) versus high dose (10mg/kg/day) CSA. Toxicity is monitored weekly for the first 2 months and then every 2 weeks until 6 months. Disease activity is assessed on a bi-monthly basis. Patients who do not develop at least a 40% improvement in disease activity at 6 months are dropped from the study, while those with a 40% or greater response continue for an additional 6 months of drug therapy. The effects of CSA on various measures of T lymphocyte function in peripheral blood and within the synovium is studied in all patients.